{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Complete response rate is defined as the proportion of participants who achieve a complete response. CR rate was to be assessed by an IRC.","groups":[{"description":"Idelalisib 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions) + rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"OG000","title":"Idelalisib + Bendamustine + Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions) + rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"OG001","title":"Placebo + Bendamustine + Rituximab"}],"populationDescription":"Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.","reportingStatus":"POSTED","title":"Complete Response Rate (CR)","type":"SECONDARY"}